
Matricelf Ltd. — Investor Relations & Filings
Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| INVESTORS PRESENTATION | 2026-01-28 | English | |
| INVESTORS PRESENTATION | 2026-01-28 | Russian | |
| COMPANY'S PRESENTATION | 2024-09-08 | Hebrew (modern) | |
| COMPANY'S PRESENTATION | 2024-09-08 | Russian | |
| INVESTORS PRESENTATION | 2024-03-27 | English | |
| INVESTORS PRESENTATION | 2024-03-27 | Russian |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
2 filings
| |||||
| 13520625 | INVESTORS PRESENTATION | 2026-01-28 | English | ||
| 13520623 | INVESTORS PRESENTATION | 2026-01-28 | Russian | ||
|
2024
4 filings
| |||||
| 6468367 | COMPANY'S PRESENTATION | 2024-09-08 | Hebrew (modern) | ||
| 6468366 | COMPANY'S PRESENTATION | 2024-09-08 | Russian | ||
| 6470518 | INVESTORS PRESENTATION | 2024-03-27 | English | ||
| 6470517 | INVESTORS PRESENTATION | 2024-03-27 | Russian | ||
|
2023
2 filings
| |||||
| 6531143 | Corporate Presentation - February2023 | 2023-02-14 | English | ||
| 6531142 | Corporate Presentation - February2023 | 2023-02-14 | Russian | ||
|
2022
2 filings
| |||||
| 6478888 | INVESTORS PRESENTATION | 2022-03-16 | English | ||
| 6478886 | INVESTORS PRESENTATION | 2022-03-16 | Russian | ||
|
2021
2 filings
| |||||
| 6482020 | Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker | 2021-06-17 | Hebrew (modern) | ||
| 6481948 | Identifying Details of New Security: MATRICELF, MATRICELF.W1 | 2021-06-14 | Hebrew (modern) | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
OS Therapies Inc
Clinical-stage immunotherapy company developing treatments …
|
OSTX | US | Professional, scientific and te… |
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
Matricelf Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/6904/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=6904 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=6904 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=6904 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 6904}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Matricelf Ltd. (id: 6904)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.